Showing 1311-1320 of 1635 results for "".
- NEI Publishes Town Hall Report on Cell-Based Products for Treating Retinal Diseasehttps://modernod.com/news/nei-publishes-town-hall-report-on-cell-based-products-for-treating-retinal-disease/2481618/Stem cell-based therapies hold great promise for replacing lost or damaged cells in the eye and restoring vision, according to The National Eye Institute, which published its Town Hall Report on cell-based products for treating retinal disease. The NEI has published "Stem cell sources a
- Researchers Found a Way to Reactivate Dormant Cells in the Retinahttps://modernod.com/news/researchers-found-a-way-to-reactivate-dormant-cells-in-the-retina/2481610/There's new hope for potentially restoring vision in patients suffering from degenerative retinal disease, thanks to work by researchers at Université de Montréal (UdeM). Published this week in Proceedings of the National Academy of Sciences, the research was
- Formosa and AimMax Submit NDA to the FDA for APP13007 for Postoperative Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/formosa-and-aimmax-announce-the-nda-submission-to-the-fda-for-app13007-for-postoperative-inflammation-and-pain-following-ocular-surgery/2481602/Formosa Pharmaceuticals and AimMax Therapeutics announced the submission of a new drug application to the FDA for APP13007, a novel aqueous nanosuspension formulation of the corticosteroid, clobetasol propionate (0.05%), for the treatment of inflammation and pain following ocular surger
- Ocumension Therapeutics Receives Priority Review Status for Zerviate New Drug Application in Chinahttps://modernod.com/news/ocumension-therapeutics-receives-priority-review-status-for-zerviate-new-drug-application-in-china/2481575/Nicox SA announced that the new drug application (NDA) for approval to commercialize Zerviate (cetirizine ophthalmic solution) 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of Natio
- NEI: Extremely Rare Gene Variants Point to a Potential Cause of AMDhttps://modernod.com/news/nei-extremely-rare-gene-variants-point-to-a-potential-cause-of-amd/2481519/A study from the National Eye Institute (NEI) identified rare genetic variants that could point to one of the general mechanisms driving age-related macular degeneration (AMD). The variants generate malformed proteins that alter the stability of the membrane attack complex (MAC), which may drive
- TearRestore’s Thermal Mask & HylaWipe Tea Tree Eyelid Wipes Now Available at Targethttps://modernod.com/news/tearrestores-thermal-mask-hylawipe-tea-tree-eyelid-wipes-now-available-at-target/2481508/TearRestore announced that its Thermal Mask and Eyelid Wipes will now be available at Target stores nationwide and at Target.com. The Thermal Mask and Eye Wipe offer alternative options to artificial tears and are designed to directly address the
- Pixium Vision Announces FDA Breakthrough Device Designation for the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd/2481505/The FDA has granted Breakthrough Device Designation to Pixium Vision's Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision implanted in human patients with atrophic dry age-related macular
- AI-based Systems Can Help Identify Rapidly Advancing Age-Related Macular Degenerationhttps://modernod.com/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration/2481490/Researchers supported by the National Eye Institute (NEI) are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within 2 years,
- NovaBay Pharmaceuticals Launches Avenova Eye Health Support to Comfort Dry Eyes and Promote Eye Healthhttps://modernod.com/news/novabay-pharmaceuticals-launches-avenova-eye-health-support-to-comfort-dry-eyes-and-promote-eye-health/2481480/NovaBay Pharmaceuticals announced the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and natural triglyceride omega-3 oils, designed to comfort dry eyes and s
- Aviceda Submits Investigational New Drug Application for AVD-104 for the Treatment of GA Associated with AMDhttps://modernod.com/news/aviceda-submits-investigational-new-drug-application-for-avd-104-for-the-treatment-of-ga-associated-with-amd/2481477/Aviceda Therapeutics announced that it has submitted an investigational new drug (IND) application to the FDA. The IND supports the use of its lead intravitreal ocular asset, AVD-104 (a novel glycan-coated nanoparticle), for the treatment of GA secondary to AMD. Aviceda previously announced